Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses
| Autor: | Michael H. Salinger, Jorge Saucedo, Charanjit S. Rihal, Jeremy J. Thaden, Ron Waksman, Kenith Fang, William W. O'Neill, Hyde M. Russell, Akhil Narang, Saibal Kar, Lowell F. Satler, Igor F. Palacios, Mackram F. Eleid, Mayra Guerrero, Brad Lewis, Christopher Meduri, Marvin H. Eng, Ignacio Inglessis, Ted Feldman, Carl L. Tommaso, Paul J. Pearson, Tatiana Kaptzan, R Makkar, Philip Krause, Jae Oh, Dee Dee Wang, Vivek Rajagopal, Isaac George, Rebecca T. Hahn, Roberto M. Lang, Mark Reisman, Ashish Pershad, Martin B. Leon, Amit Pursnani, Ujala Bokhary, Susheel Kodali |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Mitral regurgitation business.industry 030204 cardiovascular system & hematology Airway obstruction medicine.disease Surgery 03 medical and health sciences Stenosis 0302 clinical medicine medicine.anatomical_structure Swallowing Interquartile range Mitral valve Medicine 030212 general & internal medicine Heart valve Cardiology and Cardiovascular Medicine business Prospective cohort study |
| Zdroj: | JACC: Cardiovascular Interventions. 14:859-872 |
| ISSN: | 1936-8798 |
| DOI: | 10.1016/j.jcin.2021.02.027 |
| Popis: | Objectives The aim of this study was to assess 1-year clinical outcomes among high-risk patients with failed surgical mitral bioprostheses who underwent transseptal mitral valve-in-valve (MViV) with the SAPIEN 3 aortic transcatheter heart valve (THV) in the MITRAL (Mitral Implantation of Transcatheter Valves) trial. Background The MITRAL trial is the first prospective study evaluating transseptal MViV with the SAPIEN 3 aortic THV in high-risk patients with failed surgical mitral bioprostheses. Methods High-risk patients with symptomatic moderate to severe or severe mitral regurgitation (MR) or severe mitral stenosis due to failed surgical mitral bioprostheses were prospectively enrolled. The primary safety endpoint was technical success. The primary THV performance endpoint was absence of MR grade ≥2+ or mean mitral valve gradient ≥10 mm Hg (30 days and 1 year). Secondary endpoints included procedural success and all-cause mortality (30 days and 1 year). Results Thirty patients were enrolled between July 2016 and October 2017 (median age 77.5 years [interquartile range (IQR): 70.3 to 82.8 years], 63.3% women, median Society of Thoracic Surgeons score 9.4% [IQR: 5.8% to 12.0%], 80% in New York Heart Association functional class III or IV). The technical success rate was 100%. The primary performance endpoint in survivors was achieved in 96.6% (28 of 29) at 30 days and 82.8% (24 of 29) at 1 year. Thirty-day all-cause mortality was 3.3% and was unchanged at 1 year. The only death was due to airway obstruction after swallowing several pills simultaneously 29 days post-MViV. At 1-year follow-up, 89.3% of patients were in New York Heart Association functional class I or II, the median mean mitral valve gradient was 6.6 mm Hg (interquartile range: 5.5 to 8.9 mm Hg), and all patients had MR grade ≤1+. Conclusions Transseptal MViV in high-risk patients was associated with 100% technical success, low procedural complication rates, and very low mortality at 1 year. The vast majority of patients experienced significant symptom alleviation, and THV performance remained stable at 1 year. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|